Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sofosbuvir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | P2RY2 | P41231 | 6/20 | 0.45 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.45 |
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.41 |
| ▸ | DUT | P33316 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sofosbuvir SCHEMBL20733226 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL22236563 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL22236662 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL20869402 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL24134038 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL20705434 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL23348827 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL20705433 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL22236594 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 | |
| Sofosbuvir SCHEMBL19286948 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP2C9P2RY2P2RY4POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190046552-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HCV INFECTION | SPRING BANK PHARMACEUTICALS, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190046552-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HCV INFECTION | SLC10A1, HAVCR2, ABL1 | CYP3A4 215/4885CYP2C9 72/4885P2RY2 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.